Restraint of trophic factors and nutrients induces PARKIN expression

M. Klinkenberg · S. Gispert · J. A. Dominguez-Bautista · I. Braun · G. Auburger · M. Jendrach

Received: 30 August 2011 / Accepted: 10 October 2011 / Published online: 26 October 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract Parkinson’s disease (PD) is the most frequent neurodegenerative movement disorder and manifests at old age. While many details of its pathogenesis remain to be elucidated, in particular the protein and mitochondrial quality control during stress responses have been implicated in monogenic PD variants. Especially the mitochondrial kinase PINK1 and the ubiquitin ligase PARKIN are known to cooperate in autophagy after mitochondrial damage. As autophagy is also induced by loss of trophic signaling and PINK1 gene expression is modulated after deprivation of cytokines, we analyzed to what extent trophic signals and starvation stress regulate PINK1 and PARKIN expression. Time course experiments with serum deprivation and nutrient starvation of human SH-SY5Y neuroblastoma cells and primary mouse neurons demonstrated phasic induction of PINK1 transcript up to twofold and PARKIN transcript levels up to sixfold. The corresponding threefold starvation induction of PARKIN protein was limited by its translocation to lysosomes. Analysis of primary mouse cells from PINK1−/− knockout mice indicated that PARKIN induction and lysosomal translocation occurred independent of PINK1. Suppression of the PI3K-Akt-mTOR signaling by pharmacological agents modulated PARKIN expression accordingly. In conclusion, this expression survey demonstrates that PARKIN and PINK1 are coregulated during starvation and suggest a role of both PD genes in response to trophic signals and starvation stress.

Keywords Parkinson’s disease · PARKIN · PINK1 · Starvation stress · Neurodegeneration

Introduction

Parkinson’s disease (PD) is after Alzheimer’s disease the second most frequent neurodegenerative disease, with both syndromes being probably triggered by a combination of genetic predisposition and cumulative effects of environmental and physiological stressors, manifesting progressively with old age [1]. The resulting clinical movement deficit in PD is largely explained by the selective atrophy of dopaminergic neurons in the midbrain. The accumulation of ubiquitinated cytoplasmic aggregates (“Lewy bodies”) containing proteins such as α-synuclein and the appearance of oxidative stress in the affected tissues are established hallmarks of PD pathology. Rodents treated with the neurotoxins 6-OH-dopamine or the mitochondrial inhibitor 1-methyl-4-phenylpyridinium (MPP+) exhibit characteristic disease symptoms and were crucial to establish therapies. Over the past decade, the identification of more than a dozen mutant genes responsible for monogenic PD syndromes [2, 3] and another dozen PD candidate genes with significant risk association in GWAS studies [4–6] has greatly advanced our knowledge about pathogenesis, but the function of most corresponding gene products is still enigmatic and the pathways in common for both autosomal dominant and recessive PD variants remain elusive.

The PARKIN gene encoded at the PARK2 locus was identified particularly early as a frequent cause of young-onset autosomal recessive PD, and its protein sequence...
clearly codes for an ubiquitin E3 ligase [7]. Initial assumptions about its role for polyubiquitination and proteasomal protein degradation [8] are now being challenged, and its relevant substrates and its relevant loss of function are being discussed controversially, e.g., regarding mitochondrial DNA damage, autophagy, and apoptosis [9–13]. One isolated report with particularly convincing data demonstrated a role of PARKIN for receptor tyrosine kinase (RTK) endocytosis and signaling, implicating it in growth regulation [14]. PARKIN expression can be upregulated in dependence on ATF4, a transcription factor triggered by mitochondrial stress and the unfolded protein response [15].

Some PARKIN functions were shown to be downstream of Pten-induced protein kinase 1 (PINK1), a mitochondrial outer membrane kinase encoded at the autosomal recessive PARK6 locus [16, 17]. PINK1 provides protection against ROS-induced damage, and its mRNA level increases with progressive cell age [18]. Furthermore, PINK1 is transcriptionally induced in response to stress via FOXO3a and is stabilized against proteolytic degradation when the mitochondrial membrane potential dissipates [19, 20]. In Drosophila melanogaster the loss of PINK1 and PARKIN results in increased mitochondrial fission [21–23]. The role of PARKIN in mitochondrial dynamics of mammalian cells, however, is more complex and controversial as reviewed recently [24]: PINK1 was described to act as a fusion factor [23] as well as a fission factor [25, 26], while our PINK1-knockout mouse model no effect on the mitochondrial morphology of unstressed cells [27]. PINK1 and PARKIN appear to act together also in the degradation of damaged mitochondria (mitophagy) [28–31]. It was proposed that the accumulation of PINK1 protein in dysfunctional mitochondria is a prerequisite for the relocalization of PARKIN from the cytosol to the mitochondrial outer membrane [19, 28, 29]. There is ongoing debate whether this is caused via direct phosphorylation and which other proteins interact with PINK1 and PARKIN [29, 32, 33]. It is also unclear which environmental and physiological stress events play the prominent role for the PINK1/PARKIN pathway. The relevance of stress was particularly investigated for the polyubiquitin–proteasome degradation of proteins [17, 27, 34, 35], but recently, the mutation effects could be maximized when potent mitochondrial uncouplers like CCCP were used as stressor [36].

In view of the regulation of PARKIN in response to a more physiological challenge namely cytokine deprivation [20], we were interested whether the physiological competition for nutrients and growth factors which control autophagy [37] has a role in the regulation of PARKIN. A previous study reported PARKIN expression to be downregulated in SH-SY5Y neuroblastoma cells by proteasomal stress, but unchanged after oxidative stress and ER stress, while an independent study observed PARKIN upregulation in some neuroblastoma cell lines after ER stress [38, 39]. Our observations indicate that trophic deprivation and nutrient starvation cause distinct regulations of PARKIN and PINK1 in neuronal cells.

Materials and methods

Chemicals and media

Bafilomycin A1, rapamycin (all Sigma-Aldrich, Taufkirchen, Germany) and LY294002 (Jena Bioscience, Jena, Germany) stocks were prepared with DMSO and stored at −20°C until use. All cell culture media, L-glutamine, penicillin G–streptomycin solution, and minimal essential medium with Earle’s salts (MEM) nonessential amino acids were purchased from Invitrogen (Karlsruhe, Germany), DMSO and PBS were from Sigma-Aldrich (Taufkirchen, Germany).

Cell culture

SH-SY5Y cells were purchased from The European Collection of Cell Cultures (Sigma-Aldrich, Taufkirchen, Germany) and cultivated in Roswell Park Memorial Institute (RPMI) 1,640 medium containing 2 g/l D-glucose, 2 mM L-glutamine and 10% FCS. HeLa cells were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany, DSM-No. ACC57) and were cultured in MEM supplemented with 10% FCS and 1% MEM nonessential amino acids. Primary cortical neurons were isolated from 1- to 4-day-old mice as described before [27] and were kept in Neurobasal medium with 10 mM L-glutamine for 10–20 days before performing experiments. Mouse embryonic fibroblasts (MEF) were isolated from mouse embryos with standard procedures and cultivated in DMEM with 4.5 g/l D-glucose supplemented with 15% BGS (Fisher Scientific, Schwerte, Germany). All cells were kept at 37°C with 5% CO2 and 95% air.

Starvation experiments

SH-SY5Y cells were starved of trophic factors by incubating them in their normal growth medium (RPMI 1640 containing 2 g/l D-glucose and 2 mM L-glutamine) but without FCS (serum starvation). The starvation effect was maximized by incubating SH-SY5Y cells and primary neurons in HBSS (Invitrogen, nutrient starvation). HBSS contains 1.26 mM NaHCO3, 0.493 mM MgCl2 × 6H2O, 0.407 mM MgSO4 × 7H2O, 5.33 KCl, 0.441 KH2PO4, 4.17 mM NaHCO3, 137.93 mM NaCl, 0.338 mM Na2HPO4, 0.0266 mM Phenol Red, and 5.56 mM (1 g/l) D-glucose but no amino acids.

To analyze mRNA levels by real-time reverse transcription quantitative PCR (qPCR), 0.5 × 10⁶ SH-SY5Y cells

© Springer
were seeded in a six well, while 2.5 × 10⁶ SH-SY5Y cells were seeded in a 10-cm dish to investigate protein expression, always 20 h prior to experimental start. Medium was removed, cells washed with PBS and covered with 2 ml (for RNA) or 10 ml (for protein) of control medium or starvation medium as indicated in the figure captions. Neurons were starved without washing them with PBS. Afterwards cells were incubated for the appropriate time at 37°C, 95%, air and 5% CO₂. Neuron starvation experiments were performed in two to four individual neuron cultures for each genotype and time point.

RNA isolation, cDNA synthesis, and quantitative real-time PCR

Supernatant medium was collected and spun down (5 min, 500×g, 4°C). Cell pellets were combined with adherent cells, and both were washed twice with PBS. Lysis of cells and isolation of total RNA was carried out utilizing the RNeasy mini kit (QIAGEN, Hilden, Germany). For first-strand synthesis, 1 μg of total RNA was digested with DNase I and reverse transcribed with SuperScript III reverse transcriptase utilizing oligo(dT)₂₀ and random primers (all Invitrogen, Karlsruhe, Germany). Transcript changes of 30 ng cDNA per sample were analyzed in a 20-μl reaction volume with qPCR in a StepOnePlus Real-Time PCR System and the appropriate TaqMan gene expression assays (all Applied Biosystems, Darmstadt, Germany): SGK1 (Hs00178610_m1), FOXO3a (Hs00921424_m1), PINK1 (Hs00260868_m1), and PARKIN (Hs01038318_m1). Mean of expression changes was normalized to mean of TATA box-binding protein (TBP: Hs99999910_m1) as an internal control. For analysis of mRNA levels from mouse neurons, TaqMan gene expression assays pinks1 (Mm00550827_m1), parkin (Mm00450186_m1), and tbp (Mm00446973_m1) were used. Relative expression changes were calculated with the 2⁻ΔΔCt method [40] utilizing Microsoft Excel 2007 software, whereupon the ΔCt of the corresponding control served as calibrator. The resulting 2⁻ΔΔCt values of n experiments (indicated in the figures) were averaged for the appropriate time and treatment.

SDS-PAGE and western blotting

To determine PARKIN and LC3 protein expression, adherent cells were collected by scraping in 5 ml PBS supplemented with Complete EDTA free protease inhibitor (PI) cocktail (Roche Diagnostics GmbH, Mannheim, Germany), centrifuged for 5 min at 500×g, 4°C and combined with floating cells, which were likewise spun down. Cell pellets were washed twice with PBS-PI (5 min, 4°C). The resulting cell pellets were frozen in liquid nitrogen and stored at −80°C until further analysis. Proteins were extracted with 2× SDS lysis buffer (137 mM Tris/HCl pH 6.8, 4% SDS, 20% glycerol) and freshly added PhosSTOP phosphatase inhibitor and PI cocktail (all Roche Diagnostics GmbH, Mannheim, Germany). Samples were sonicated (5 s, 3 cycles × 10%, 40% power) with a Sonopuls UW2070 ultrasonic homogenizer to advance cell lysis, to destroy DNA and to homogenize the samples. Afterwards samples were spun down (20 min, 16,100×g, RT). Subsequently protein concentration was determined with the BC assay protein quantitation kit (VWR, Darmstadt, Germany). To investigate PARKIN expression, 30 μg protein per sample, prepared with 6× Laemmli sample buffer, were boiled for 5 min at 95°C and separated on a 10% SDS gel. Proteins were transferred to nitrocellulose membrane (Whatman, Dassel, Germany) by wet blotting (50 V, 90 min). Membranes were blocked for 1 h with 5% skim milk powder/TBS–Tween (0.05%) and probed with primary monoclonal (clone PRK8) mouse anti-PARKIN [41] antibody (New England Biolabs, Frankfurt, Germany) at titer 1:1,000 overnight at 4°C. Specificity of anti-PARKIN antibody was controlled utilizing PARKIN-knockout (ko) and wild-type (wt) mouse brain samples. Quantification of PARKIN and equal protein loading was controlled by normalization to GAPDH (monoclonal (6C5) antiamouse, 1:15,000; Merck, Darmstadt, Germany). Primary antibodies were detected with IRDye 800CW conjugated goat antiamouse IgG secondary antibody (1:20,000, 1 h, RT) on the Odyssey Infrared Imaging System (both LI-COR, Bad Homburg, Germany). Band intensities were measured with the appropriate Odyssey software, and protein expression ratios were calculated with Microsoft Excel 2007 software. To investigate autophagosome formation 30 μg protein from each sample were separated on a NuPage 12% Bis–Tris precast gel utilizing 1× NuPage MOPS SDS running buffer (both Invitrogen, Karlsruhe, Germany). LC3 protein was detected through chemiluminescence on a PVDF membrane (Bio-Rad Laboratories, Munich, Germany). Samples were probed with a monoclonal antimonoclonal LC3 (clone 2G6) antibody (Nanotools, Tenningen, Germany) at titer 1:500. Primary antibody was detected with a secondary ECL antiamouse IgG HRP-linked antibody (Amersham Biosciences, Glattbrugg Switzerland) at titer 1:15,000 on ECL hyperfilm (Amersham Biosciences). The ratio of LC3-II/GAPDH expression was determined by quantification of the western blot with ImageJ.

Constructs and transfection

GFP-PARKIN has been described previously [42]. To obtain cherry-GFP-PARKIN an existing cherry-GFP fusion protein was digested with BspEI and BamH1 to remove the insert. Into these sites the PARKIN ORF was cloned after digestion with BspEI and BamH1. All constructs were verified by sequencing. SH-SY5Y cells
and MEF were transfected by electroporation with the cell line transfection kit V respective with the MEF transfection kit and the Nucleofector II (all Lonza, Basel, Switzerland) according to the manufacturer’s instruction. HeLa cells were transfected with Effectene (Qiagen, Hilden, Germany) likewise according to the manufacturer’s instruction.

Confocal laser scanning microscopy and immunostaining

LAMP-1 and LAMP-2 were detected with anti-LAMP-1 CD 107A and anti-LAMP-2 CD 107B antibody, while p62/ SQSTM1 was detected with anti-p62 Ick ligand as primary antibody (all BD Bioscience, Heidelberg, Germany). Cy2-conjugated Affini Pure Donkey antimouse IgG (H+L) antibody served as secondary antibody (Dianova, Hamburg, Germany). All microscopic analyses were performed with a Leica TCS SP5 confocal laser scanning microscope equipped with the appropriate filters and a HCX PL APO lambda blue 63.0×, 1.40 OIL UV objective that was controlled by the LAS AF scan software (version 1.8.2) (Leica Microsystems, Wetzlar, Germany). Pictures were visualized with IMARIS 6.0.0 (BITPLANE Scientific solutions), and no deconvolution was performed. Images were maximum image projections apart from the insets in Fig. 3c, d which represent single slices.

Statistics

Raw data generated with Microsoft Excel 2007 were transferred to GraphPad Prism 4.03 software to calculate mean, SEM, and P values. For qPCR significance was calculated by unpaired t test between mean of 2−ΔΔCt values under different conditions, e.g., nonstarved (RPMI+FCS) vs. starved (HBSS−FCS) for the corresponding time. Experimental variation was whenever possible (qPCR) calculated by averaging ΔΔCt values of the controls of n experiments and generating 2−ΔΔCt values. SEM is indicated by error bar in the figures. One-way ANOVA followed by Tukey posttest was used to calculate statistics for PARKIN protein expression change (Fig. 2b) and mRNA changes of primary neurons (Fig. 5). P values smaller than 0.05-fold were considered to be significantly different: *P≤0.05, **P≤0.01, and *** P≤0.001.

Results

Serum deprivation of SH-SY5Y neuroblastoma cells results in decreased SGK1 and increased FOXO3a, PINK1, and PARKIN transcript levels

In view of the role of PINK1 in the stress response pathway of cytokine deprivation [20], we aimed to gain a deeper understanding of PARKIN, which is putatively acting downstream of PINK1 in the signaling network. As first step we analyzed the PARKIN mRNA expression in different cell systems used as PD models. HEK-293 cells exhibited low PARKIN mRNA levels, while HeLa cells, which were used as control, contained no PARKIN as shown before [41, 43] (Fig. S1). In contrast, fibroblasts had a very high PARKIN transcript expression and the expression levels of the human dopaminergic neuroblastoma cell line SH-SY5Y lay between fibroblasts and HEK-293 cells. Since PD affects preferentially the dopaminergic nigrostriatal projection, we chose the SH-SY5Y cells as the best characterized and established PD in vitro model system. We subjected SH-SY5Y to serum deprivation by incubating them in RPMI medium with 2 g/l D-glucose and 2 mM l-glutamine but without FCS and compared them to cells incubated in RPMI medium with 10% FCS. Cells were subjected to a 72-h time course, and the transcript levels of PARKIN, PINK1, and the transcription factor FOXO3a, which is known to upregulate PINK1 expression as part of an antiapoptotic response to cytokine withdrawal [20], were analyzed. FOXO3a itself was observed to aggregate in Lewy bodies and is thus implicated in the pathogenesis of PD [44]. Serum/glucocorticoid-regulated kinase 1 (SGK1) was used as a positive control in view of the known strong dependence of its transcript levels from serum availability; furthermore, SGK1 is known to inhibit FOXO3a function via phosphorylation and it shows altered expression in the MPP+ mouse model of PD [45, 46].

In SH-SY5Y cultivated without FCS, reductions of SGK1 appeared already at 2 h, became significant from 4 until 24 h, and were discernible until 72 h, with a peak of five- to 10-fold downregulation at 12–24 h (Fig. 1). These alterations were paralleled by the expected, approximately 1.5-fold significant induction of FOXO3a already at 2 h, which lasted until 12–24 h, followed by a gradual decline to the baseline by 72 h. They were also paralleled by a delayed, approximately 1.5-fold significant induction of PINK1 levels between 8 and 24 h, and a return to the baseline at 48 h. The main finding of this experiment presents the relatively early and high induction of PARKIN levels, significant from 4 to 24 h, that reached threefold values over starting levels at 12 h and returned to baseline values by 48–72 h (Fig. 1), demonstrating that PARKIN expression strongly depends on the presence of trophic factors.

Additional nutrient starvation doubles the levels of PARKIN and PINK1 mRNA induction in SH-SY5Y cells

To investigate if the induction of PINK1 and PARKIN mRNA is part of a graded response to trophic deprivation,
the starvation stress was maximized by additional deprivation from nutrients through a switch from RPMI medium with 10% FCS to HBSS medium (1 g/l D-glucose, no serum or amino acids, specific composition see “Material and methods” section). Again mRNA levels of SGK1 were maintained until 12 h under control conditions, but showed significant reductions under starvation conditions with a similar time course as in Fig. 1 and a peak again at 12 h, but a stronger effect with more than 10-fold changes between 8 and 16 h (Fig. 2a). As with serum deprivation alone, FOXO3a transcript levels were already significantly upregulated at 2 h and reached an approximately 1.5-fold induction by 4 h, but the upregulation was no longer significant at 8 and 12 h suggesting that the additional effects of nutrient starvation are mediated by further factors. The induction of PINK1 mRNA levels was enhanced to twofold values, with a peak and clear significance by 12 and 16 h as previously, but curiously a lack of significance at 8 and 24 h in comparison to serum deprivation alone. In contrast, the induction of PARKIN mRNA levels was markedly enhanced until sixfold, again with a similar time course of significant changes between 8 and 24 h and a peak by 12–16 h, but no return to the baseline even after 72 h (Fig. 2a).

To assess whether this strong PARKIN mRNA induction served to increase PARKIN protein levels or to maintain PARKIN protein levels in compensation of autophagic degradation, immunoblot analyses of PARKIN protein levels were performed (Fig. 2b). Gradual increases of the major 52-kDa and the minor 48-kDa PARKIN isoforms until 72 h after starvation were observed without exhibiting differences, peaking at an approximately threefold induction with high significance at 72 h. In conclusion, qPCR and immunoblot data in neural cells confirm a graded upregulation of PARKIN expression in response to serum and nutrient withdrawal, suggesting a protective function of PARKIN in periods of starvation.

Starvation-induced translocation of PARKIN to lysosomes

In view of the established role of PARKIN in mitophagy [47], we hypothesized that the induction of PARKIN expression during deprivation of trophic factors is related to a putative function in the starvation-induced autophagic degradation of proteins and/or organelles. To investigate a possible role of PARKIN in the autophagolysosomal pathway, the fusion protein cherry-GFP-PARKIN was constructed. As the green GFP fluorescence is sensitive towards acidity while the red cherry fluorescence is stable under acid conditions, the presence of PARKIN in acid-containing lysosomes can be monitored by the loss of its green fluorescence [48]. Microscopical analysis of transfected SH-SY5Y neuroblastoma cells exhibited green and red cytosolic fluorescence in a diffuse distribution throughout the cytosol at time points 2 and 4 h [Fig. 3a (a–b and h–i)]. However, starting from 8 h with a maximum around 16 h an increasing percentage of starved cells in HBSS medium contained PARKIN punctae [Fig. 3a (j–n)] emitting only red, but no green fluorescence. In contrast, control cells kept in RPMI medium with 10% FCS showed similar PARKIN punctae only much later (24–48 h) and in a
lower amount per cell [Fig. 3a (f–g)]. At the end of the observation period (48 h), the general amount of PARKIN punctae in starved cells was reduced compared to the 16 h peak and was similar under both conditions. These data indicate that starvation triggered a phasic response of PARKIN peaking at 16 h, with subcellular relocalization and acid exposure, compatible with an association of PARKIN with proteins or organelles that are degraded by the autophago-lysosomal pathway.

To corroborate this notion, HeLa cells transfected with cherry-GFP-Parkin were subjected to starvation medium (HBSS−FCS). HeLa cells were chosen for this experiment since these cells do not contain endogenous PARKIN [41, 43] and are morphologically better for high-resolution microsco-
To further support the activation of PARKIN expression by bafilomycin A1 and LY294002, can be mimicked by rapamycin or LY294002 and repressed. The starvation effect on PARKIN expression is expected to enhance the starvation effect, while both bafilomycin A1 exerted no influence (Fig. 4a, BAF, white bar), while the rapamycin and LY294002 were able to upregulate PARKIN mRNA significantly up to twofold (RAP, LY, white bars). Similar to previous observations, starvation triggered a fourfold PARKIN mRNA induction compared to the PARKIN mRNA levels at 16 h in unstarved cells (Fig. 4a, CON, black bar). In starved cells (black bars), rapamycin treatment failed as expected to enhance the starvation effect, while both bafilomycin A1 and LY294002 limited the PARKIN induction from fourfold to twofold, correlating with an impaired PARKIN usage after bafilomycin A1 treatment (Fig. 3b). The repressing effect of LY294002 here may be explained by its known autophagy inhibition effects [50]. To validate these mRNA data, the levels of endogenous PARKIN protein after 24 h were determined by immunoblot analysis (Fig. 4b). In good agreement with the transcript levels, PARKIN protein levels were visibly enhanced in unstarved cells by rapamycin or LY294002 and in starved cells treated only with DMSO. Treatment of starved cells with bafilomycin A1 or LY294002 resulted in evident PARKIN reduction. Overall, the treatment of starved and unstarved cells with pharmacological agents supports our notion that PARKIN expression is indeed regulated by trophic signaling via the PI3K-Akt-mTOR pathway.

Starvation-triggered PARKIN induction in primary neurons and PARKIN relocalization in embryonal mouse fibroblasts occur independent of PINK1 expression

As PARKIN and PINK1 are both induced by starvation and PARKIN is known to rescue some PINK1 deficiency phenotypes and is therefore thought to act downstream of PINK1 [26, 51] and PINK1 is necessary for CCCP-induced PARKIN translocation to mitochondria [28], we investigated whether the starvation-triggered PARKIN induction depends on PINK1. For this purpose, ex vivo primary cortical neuron cultures (DIV 14) of wt and PINK1-ko mice bred from littermates [27] were subjected to starvation stress. Significant inductions from 4 h on with a threefold peak around 8 h were observed for PARKIN mRNA levels both in wt and ko cells and for PINK1 mRNA in wt cells (Fig. 5a, b). These findings indicate that starvation-triggered PARKIN transcription is not controlled by PINK1 expression and are in agreement with the previous data from neuroblastoma cells where a significant upregulation occurred earlier for PARKIN than for PINK1 (Figs. 1 and 2).

To test whether the loss of PINK1 affects PARKIN translocation to lysosomes, MEF from wt and PINK1-ko...
animals were transfected with the cherry-GFP-Parkin construct. After 2 days MEF were incubated either with control medium containing 15% bovine growth serum (DMEM+BGS) or with starvation medium (HBSS−BGS) for 16 h. Confocal microscopy analysis demonstrated similar formation of red PARKIN punctae in MEF from wt and PINK1-ko mice (Fig. S2), confirming the PINK1 independence of PARKIN induction and lysosomal translocation during starvation.

In summary, their regulation pattern after drug exposure and their phasic induction during starvation but not during ER or oxidative stress [38] indicate that PARKIN and PINK1 are coregulated during trophic deprivation and undergo parallel fates or play similar roles in response to starvation.

**Discussion**

In this study we investigated the involvement and the regulation of parkinsonism-related genes in response to serum and nutrient starvation. Our expression analyses document a prominent role for PARKIN in growth factor signaling: during unavailability of serum and nutrients, neural SH-SY5Y cells induce PARKIN more than other published pathway components [20] in a phasic pattern for mRNA levels at 8–24 h after starvation, in a process dependent on PI3K-Akt-mTOR signaling and autophagy. These data are supported by alterations of PARKIN mRNA levels after application of pharmacological drugs targeting the PI3K-Akt-mTOR pathway, as we found a significant upregulation of the PARKIN transcript in unstarved cells after specific inhibition of the PI3K-Akt-mTOR phosphorylation cascade either through LY294002 or through rapamycin. The PI3K-Akt signaling is involved in a number of different pathways including cell growth, proliferation, cell cycle control, cell migration and invasion, survival, protein, glycogen and fatty acid synthesis [52]. While the upregulation of PARKIN mRNA in unstarved cells after LY294002 treatment is most probably due to LY294002’s ability to mimic starvation, it could be also additionally a compensatory antiapoptotic mechanism. As Akt blocks Bax conformation changes and mitochondrial translocation [53, 54] and PARKIN has antiapoptotic properties [55–58], an increase of the PARKIN transcript could therefore compensate for the LY294002-mediated inhibition of Akt.

Our results are compatible with strong biochemical evidence in peripheral cell types showing the ubiquitin E3 ligase PARKIN able to modulate EGF receptor trafficking and promote PI3K-Akt signaling through a direct interaction between the PARKIN ubiquitin-like (Ubl) domain and the ubiquitin-interacting motif of the protein Eps15, a component of the RTK endocytosis machinery [14], indicating that PARKIN function affects RTK signaling and that a dysregulation could be relevant for the nervous system.

Published data about transcriptional dysregulation in PD are scarce and usually not controlled by time course analyses, in spite of the intense investigations into PD pathogenesis and into the dozens novel PD genes over the past decade [59]. A genome-wide survey of the brain transcriptome from the MPP+-treated mouse model of PD identified an upregulated expression of the immediate early gene SGK1 as the prominent effect [46]. SGK1 transcription is strongly stimulated by serum or specific growth factors such as insulin but also by other stressors such as high glucose concentrations or oxidative stress and is activated by PI3K signaling [60]. SGK1 exerts an antiapoptotic effect through its inhibitory phosphorylation of FOXO3a and BAD [61]. The transcription factor FOXO3a is induced by nutrient restriction and oxidative stress, is inhibited by Akt-signaling, and mediates the protective upregulation of antioxidant proteins such as MnSOD and later the proapoptotic regulation of FasL, Bim, and Bel-6 [62]. FOXO3a was observed to be sequestered into Lewy bodies, the pathognomonic protein aggregates in neurons affected by PD [44]. Thus, SGK1 and FOXO3a represent credible examples of transcriptional dysregulation in PD, both being implicated in stress-dependent PI3K-Akt growth signaling.

Our analysis whether PARKIN expression levels depended on the presence of serum growth factors showed similarly strong effects early on for FOXO3a and SGK1, later for PARKIN and PINK1 in dopaminergic neuronal cells (Fig. 1). This effect could be maximized to a twofold PINK1 transcript induction and sixfold PARKIN induction upon the additional removal of nutrients from the culture medium (Fig. 2). This transcript induction served not only to compensate the ongoing PARKIN protein sequestration in autophagosomes and lysosomes (Fig. 3), but was sufficient.
to elevate the PARKIN protein steady-state levels threefold after 36 h in a sustained fashion, suggesting that PARKIN is specifically needed during this period, hours after maximal LC3-II conversion and induction of lysosomal degradation (compare the time courses for PARKIN protein and LC3-II in Figs. 2b and 3a, f). A degradation of PARKIN by lysosomes was implicated after CCCP treatment [28, 29, 63], and our data show that inhibition of the autophago-lysosomal pathway during starvation, e.g., by bafilomycin A1 significantly reduced PARKIN mRNA levels, indicating a similar fate for PARKIN during starvation. However, CCCP-induced PARKIN degradation was dependent on PINK1, while
starvation-triggered PARKIN induction became significant before the PINK1 induction (Fig. 2), and appeared independent from PINK1 (Fig. 5), suggesting only partially shared upstream regulation mechanisms and implying that PARKIN participates in different pathways in stress response depending on the specific stressor.

Thus, serum deprivation and nutrient starvation result not only in the known early expression regulation of FOXO3a and SGK1 during the early period of growth factor signaling and autophagosome formation (until 12 h in our assay, see Fig. 3f) but also in a later strong upregulation of PARKIN and PINK1 levels, which could exert protective antiapoptotic effects [64]. The data are compatible with the previously reported dependence of PINK1 expression on the activity of the phosphatase PTEN, which antagonizes the PI3K-Akt-mTOR kinase signaling cascade [65]. Cell type-specific regulation of PARKIN had already been noted after ER or proteasomal stress [38, 39], but a time course correlation of

---

**Fig. 4** Pharmacological modulation of PARKIN expression. a SH-SY5Y cells were treated with control (RPMI+FCS) or starvation medium (HBSS−FCS) containing either 0.05% DMSO, 5 nM bafilomycin A1 (BAF), 0.5 μM rapamycin (RAP), 25 μM LY294002 (LY), or nothing (CON) and incubated for 16 h. Significance was determined between unstarved cells (white bar, CON) and unstarved treated cells as well as between starved cells (black bar, CON) and starved treated cells. Analysis of PARKIN mRNA demonstrated clearly its modulation by the applied drugs; n = 4. b SH-SY5Y cells were treated as in a and after 24 h PARKIN expression levels were determined by western blot, supporting the mRNA data presented in a.

---

**Fig. 5** Starvation-triggered PARKIN induction and translocation to lysosomes occur independent of PINK1 expression. Primary neuron cultures of wild-type (wt) and PINK1-knockout mice (ko) littermates were starved with HBSS medium or nonstarved for 24 h (CON). a PINK1 and b PARKIN mRNA levels were analyzed by qPCR, indicating that the PARKIN induction is independent of

---

© Springer
this effect to cellular processes or an investigation into the mechanisms involved was not attempted, except an identification of ATF4 as transcription factor of PARKIN [15].

In conclusion, our systematic expression studies of dopaminergic neural cells documented in a time course over 72 h after starvation and treated with drugs to modulate specific pathways all consistently point to an important role of PARKIN and PINK1 in the serum- and nutrient-dependent signaling, suggesting that they act closely together in this pathway. It would be interesting to investigate whether additional parkinsonism-relevant genes are involved in the same signaling network; similar expression profiling studies could be useful to screen novel disease-associated candidate genes and elucidate their putative roles in stress response pathways.

Acknowledgments We thank Tessa Frielinghaus and Birgitt Meseck-Selechow for the technical assistance and further support.

Financial support This work was supported by grants of the German Federal Ministry of Education (BMBF 01GS08138), through the National Genome Research Network (NGFNplus), and the GerontoMitoSys network (BMBF PTK 0315584A).

Ethical standards The authors declare that the experiments comply with the current laws of the country in which they were performed.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Gasser T (2009) Mendelian forms of Parkinson’s disease. Biochim Biophys Acta 1792(7):587–596
2. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chardardskharapprsa S, Athanasiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson disease. Science 276(5321):2045–2047
3. Klein C, Schneider SA, Lang AE (2009) Hereditary parkinsonism: Parkinson disease look-alikes—an algorithm for clinicians to diagnose “PARK” genes and beyond. Mov Disord 24(14):2042–2058
4. Simon-Sanchez J, Schulte C, Bras JM, Shamsa M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houliden H, Steffens M, Okum MS, Raceette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonoi Z, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzezk A, Park Y, Hallenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41(12):1308–1312
5. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41(12):1303–1307
6. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simon-Sanchez J, Schulte C, Lesage S, Sveinbjornsdottir S, Stefansson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377 (9766):641–649
7. Kitada T, Asakawa S, Hattori N, Matsunaga H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6765):605–608
8. Tanaka K, Suzuki T, Hattori N, Mizuno Y (2004) Ubiquitin, proteasome and parkin. Biochim Biophys Acta 1695(1–3):235–247
9. Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to Parkinson’s disease? EMBO Rep 5(7):681–685
10. Lim KL, Dawson VL, Dawson TM (2006) Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson’s and other conformational diseases? Neurobiol Aging 27(4):524–529
11. Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Stenroos ES, Tharainisodottir T, Brice A, van Bergen En Henegouwen PM, Fon EA (2006) A regulated interaction with the UIM protein Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18(20):3832–3850
12. Chen D, Gao F, Li B, Wang H, Xu Y, Zhu C, Wang G (2010) Parkin mono-ubiquitinates Bel-2 and regulates autophagy. J Biol Chem 285(49):38214–38223
13. Vives-Bauza C, Przedborski S (2011) Mitophagy: the latest problem for Parkinson’s disease. Trends Mol Med 17(3):158–165
14. Fallon L, Belanger CM, Corera AT, Kontogiannea M, Regan-Klapisz E, Moreau F, Voortman J, Haber M, Rouleau G, Thorarinssdottir T, Brice A, van Bergen En Henegouwen PM, Fon EA (2006) A regulated interaction with the UIM protein Eps15 implicated in parkin expression and trafficking and P3(9)K-Akt signalling. Nat Cell Biol 8(8):834–842
15. Bouman L, Schlief A, Lutz AK, Shan J, Deleinie A, Kast J, Galeydar Z, Palmsano V, Patenge N, Berg D, Gasser T, Augustin R, Trumbach D, Ircher J, Park DS, Wurst W, Kilberg MS, Tatetz J, Winklhofer KF (2011) Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ 18:769–782
16. Zhou C, Huang Y, Shao Y, May J, Prout D, Perier C, Dauer W, Schon EA, Przedborski S (2008) The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A 105(33):12022–12027
17. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Alto Z, Del Turco D, Bentivoglio AR, Healy DG, Balestri M, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houliden H, Steffens M, Okum MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonoi Z, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzekz A, Park Y, Hallenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2010) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41(12):1308–1312
18. Mai S, Klinkenberg M, Auburger G, Bereiter-Hahn J, Jendrach M, Rothfuss O, Fischer H, Hasegawa T, Maisel M, Leitner P, Tharainisodottir T, Brice A, van Bergen En Henegouwen PM, Fon EA (2006) A regulated interaction with the UIM protein Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18(20):3832–3850
19. Jin SM, Lazarou M, Yang C, Kane LA, Narendra DP, Youle RJ (2010) Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. J Cell Biol 191(5):933–942
20. Mei Y, Zhang Y, Yamamoto K, Xie W, Mak TW, You H (2009) FOXO3a-dependent regulation of Pink1 (Park6) mediates survival signaling in response to cytokine deprivation. Proc Natl Acad Sci U S A 106(13):5153–5158

21. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 105(5):1638–1643

22. Deng H, Dodson MW, Huang H, Guo M (2008) The Parkinson’s disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci U S A 105(18):14503–14508.

23. Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, Vogel H, Lu B (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A 105(19):7070–7075

24. Jendrach M, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G (2009) The mitochondrial kinase PINK1, stress response and Parkinson’s disease. J Bioenerg Biomembr 41(6):481–486

25. Dagda RK, Cherra SJ 3rd, Kulich SM, Tandon A, Park D, Chu CT (2009) Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 284(20):13843–13855

26. Exner N, Treske B, Paquet D, Holmstrom K, Schiesling C, Exner V, Fassler R, Winklhofer KF, Vogel F, Reichert AS, Auburger G, Klinkenberg M, Thurow N, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G (2009) The mitochondrial kinase PINK1, stress response and Parkinson’s disease. J Bioenerg Biomembr 41(6):481–486

27. Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G (2009) The mitochondrial kinase PINK1, stress response and Parkinson’s disease. J Bioenerg Biomembr 41(6):481–486

28. Gispert S, Ricciardi F, Kurz A, Garcia-Arencibia M, Fernandez-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert AS, Auburger G (2009) Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 4(6):e5777

29. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Klinkenberg M, Thurow N, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G (2009) The mitochondrial kinase PINK1, stress response and Parkinson’s disease. J Bioenerg Biomembr 41(6):481–486

30. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Klinkenberg M, Thurow N, Gispert S, Ricciardi F, Klinkenberg M, Schemm R, Auburger G (2009) The mitochondrial kinase PINK1, stress response and Parkinson’s disease. J Bioenerg Biomembr 41(6):481–486

31. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

32. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

33. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

34. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

35. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

36. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

37. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

38. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

39. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

40. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

41. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

42. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

43. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

44. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

45. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

46. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

47. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

48. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

49. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

50. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

51. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

52. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

53. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

54. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32

55. Kawashima H, Asano S, Ishimori K, Takeda A, Castellani RJ, Perry G, Smith MA, Zhu X, Lee HG (2009) Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson’s disease. Mol Neurodegener 4:32
52. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274
53. Yamaguchi H, Wang HG (2001) The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20(53):7779–7786
54. Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL, Henson PM (2004) Phosphorylation of Bax Ser218 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279(20):21085–21095
55. Jiang H, Ren Y, Zhao J, Feng J (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13(16):1745–1754
56. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease. Proc Natl Acad Sci U S A 101(50):17510–17515
57. Berger AK, Cortese GP, Amodeo KD, Weihofen A, LaViole MJ (2009) Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. Hum Mol Genet 18(22):4317–4328
58. Hwang S, Kim D, Choi G, An SW, Hong YK, Suh YS, Lee MJ, Cho KS (2010) Parkin suppresses c-Jun N-terminal kinase-induced cell death via transcriptional regulation in Drosophila. Mol Cells 29(6):575–580
59. Crosiers D, Theuns J, Cras P, Van Broeckhoven C (2011) Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42(2):131–141
60. Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL (1993) Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 13(4):2031–2040
61. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V (2006) (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiol Rev 86(4):1151–1178
62. Storz P (2011) Forkhead homebox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal 14(4):593–605
63. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183(5):795–803
64. Fitzgerald JC, Plun-Favreau H (2008) Emerging pathways in genetic Parkinson’s disease: autosomal-recessive genes in Parkinson’s disease—a common pathway? FEBS J 275(23):5758–5766
65. Unoki M, Nakamura Y (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20(33):4457–4465